THE CARDIAC BIOMARKER, NT-PRO BNP, AND HEMODYNAMIC PARAMETER, PCWP IN PATIENTS UNDERGOING ON-PUMP CABG SURGERY

GURPREET SINGH OBEROI; RAJWINDER KAUR

doi:10.22159/ajpcr.2025v18i5.54207

Authors

GURPREET SINGH OBEROI Department of Cardiovascular and Thoracic Surgery, Geetanjali Medical College and Hospital, Udaipur, Rajasthan, India
RAJWINDER KAUR Department of Respiratory Medicine, Geetanjali Medical College and Hospital, Udaipur, Rajasthan, India.

DOI:

https://doi.org/10.22159/ajpcr.2025v18i5.54207

Keywords:

Coronary artery bypass grafting procedures, N-terminal pro-brain natriuretic peptide biomarker, Pulmonary capillary wedge pressure, Cardiovascular diseases, Coronary artery disease

Abstract

Objective: This study aimed to investigate the correlation between preoperative N-terminal pro-brain natriuretic peptide (NT-proBNP) levels and intraoperative pulmonary capillary wedge pressure (PCWP) in patients undergoing on-pump coronary artery bypass grafting (CABG).

Methods: Pre-operative blood samples were collected to assess NT-proBNP levels. During surgery, PCWP and other hemodynamic parameters were measured using a Swan-Ganz catheter. Plasma dobutamine levels were evaluated 4 h post-incision. Statistical analysis was performed to identify correlations between biomarkers and hemodynamic data.

Results: Pre-operative NT-proBNP levels demonstrated a strong correlation with intraoperative PCWP (r=−0.84, p<0.05), suggesting its potential as a predictor for low cardiac output syndrome.

Conclusion: NT-proBNP emerges as a valuable biomarker for identifying patients at risk of hemodynamic instability during on-pump CABG procedures. Continuous monitoring of NT-proBNP and PCWP could facilitate risk assessment and improve intraoperative care.

Downloads

Download data is not yet available.

References

Justyn M, Yulianti T, Wilar G. Long-Term Covid-19 effect to endothelial damage trough extrinsic apoptosis led to cardiovascular disease progression: an update review. Int J Appl Pharm. 2023;15:60-8.

Khairnar N, Pingale P, Amrutkar S. Role of micronutrients in heart diseases. Int J Curr Pharm Res. 2021;13:1-5.

Alexander JH, Smith PK. Coronary-artery Bypass grafting. N Engl J Med. 2016;374(20):1954-64. doi: 10.1056/NEJMra1406944

Coats AJ, Anker SD, Baumbach A, Alfieri O, Von Bardeleben RS, Bauersachs J, et al. The management of secondary mitral regurgitation in patients with heart failure: A joint position statement from the heart failure association (HFA), European association of cardiovascular imaging (EACVI). European heart rhythm association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. Eur Heart J. 2021;42:1254-69.

DeFilippi CR, Christenson RH, Gottdiener JS, Kop WJ, Seliger SL. Cardiol. 2010;55(5):441-50.

Oremus M, Don-Wauchope A, McKelvie R, Santaguida PL, Hill S, Balion C, et al. BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure. Heart Fail Rev. 2014;19(4):471-505. doi: 10.1007/s10741-014-9439-6, PMID 24986335

Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley MA. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA. 2007;297(2):169-76. doi: 10.1001/jama.297.2.169, PMID 17213400

Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez- Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: An international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP study. Eur Heart J. 2006;27(3):330-7. doi: 10.1093/eurheartj/ ehi631, PMID 16293638

Daubert MA, Yow E, Barnhart HX, Piña IL, Ahmad T, Leifer E, et al. Differences in NT‐proBNP response and prognosis in men and women with heart failure with reduced ejection fraction. J Am Heart Assoc. 2021;10(10):e019712. doi: 10.1161/JAHA.120.019712, PMID 33955231

Cerrahoglu M, Iskesen I, Tekin C, Onur E, Yildirim F, Sirin BH. N-terminal proBNP levels can predict cardiac failure after cardiac surgery. Circ J. 2007;71(1):79-83. doi: 10.1253/circj.71.79, PMID 17186982

Rothenburger M, Stypmann J, Bruch C, Wichter T, Hoppe M, Drees G, et al. Aminoterminal B-type Pro-Natriuretic peptide as a marker of recovery after high-risk coronary artery bypass grafting in patients with ischemic heart disease and severe impaired left ventricular function. J Heart Lung Transplant. 2006;25(5):596-602. doi: 10.1016/j. healun.2005.12.006, PMID 16678040

Fonarow GC. The treatment targets in acute decompensated heart failure. Rev Cardiovasc Med. 2001;2 Suppl 2:S7-S12. PMID 12439356

Forfia PR, Watkins SP, Rame JE, Stewart KJ, Shapiro EP. Relationship between B-Type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol. 2005;45(10):1667- 71. doi: 10.1016/j.jacc.2005.01.046, PMID 15893185

Harrison A, Morrison LK, Krishnaswamy P, Kazanegra R, Clopton P, Dao Q, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med. 2002;39(2):131-8.

Kazanegra R, Cheng V, Garcia A, Krishnaswamy P, Gardetto N, Clopton P, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: A pilot study. J Card Fail. 2001;7(1):21-9. doi: 10.1054/ jcaf.2001.23355, PMID 11264546